Down down prices are down.
Looks like some have lost patience. LMAO. Dudded!!!! Oops, hang on, I recall Mss Josie Cow stating that COLOSTAT had a very high sensitivity and specificity when it came to identifying Advanced Adenomas.
In conclusion, in an average-risk American population, the cfDNA blood test has a sensitivity of 83% for detecting CRC and a specificity of 90% for advanced neoplasias. However, it seems virtually incapable of detecting advanced polyps, with a sensitivity of only 13%. It therefore serves as an early detection tool for asymptomatic CRC but does not contribute to its prevention.
Prevention still relies on stool use to detect advanced polyps, which are the only true precancerous lesions. The gain from mtfDNA stool testing is thus modest compared with FIT, the gold standard with low cost and high specificity for this indication. To date, some European countries have applied the principle of informed choice for eligible individuals with two jointly proposed screening methods: A screening colonoscopy every 10 years or a biennial FIT followed by a colonoscopy in case of positivity.
